Blocked pathways: FTIs shut down oncogene signals

Saïd M Sebti1

  • 1Drug Discovery Program, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida 33612, USA. sebti@moffitt.usf.edu

The Oncologist
|December 13, 2003
PubMed

Insights

Targeting Ras protein prenylation with farnesyl transferase inhibitors offers a novel cancer therapy. These inhibitors disrupt cell cycle progression and tumor growth by blocking key signaling pathways and protein modifications.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Ras proteins are crucial for cell signaling, regulating growth, differentiation, and survival.
  • Ras mutations are common in human cancers, driving tumorigenesis.
  • Prenylation (farnesylation or geranylgeranylation) is essential for Ras protein localization and activation.

Purpose of the Study:

  • To explore the potential of inhibiting farnesyl transferase and geranylgeranyl transferase as a targeted cancer therapy.
  • To elucidate the mechanisms by which these inhibitors suppress tumor growth.

Main Methods:

  • Investigating the effects of geranylgeranyl transferase inhibitors on cell cycle progression.
  • Analyzing the impact of farnesyl transferase inhibitors on bipolar spindle formation and cell cycle arrest.
  • Exploring the role of phosphoinositide-3-OH kinase/Akt pathways in the antitumor activity of farnesyl transferase inhibitors.

Main Results:

  • Geranylgeranyl transferase inhibitors cause G(1)/S cell cycle arrest, suppressing tumor growth.
  • Farnesyl transferase inhibitors inhibit bipolar spindle formation, blocking mitotic progression.
  • Inhibition of PI3K/Akt pathways may contribute to the antitumor effects of farnesyl transferase inhibitors in some cancers.

Conclusions:

  • Inhibiting Ras prenylation enzymes is a promising targeted cancer therapy strategy.
  • Further research is needed to identify specific farnesylated protein targets and predictive molecular signatures for patient selection.

Related Concept Videos

Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...